After conducting a meta-analysis of the supporting preclinical application materials submitted to institutional review boards (IRBs) for more than 100 clinical trials, researchers at the German Hannover Medical School found that those application materials were deficient in the vast majority of applications, to the point that "poor [preclinical efficacy studies] design and reporting thwart risk/benefit evaluation during ethical review of phase I/II studies."
The Cancer Genome Atlas, a comprehensive program that used sequencing to understand the genomic landscapes of 33 different tumor types, published its results in almost 30 papers in half a dozen different Cell Press journals.
Healthy brains continue to generate new neurons into old age, though they show reduced neural plasticity and angiogenesis, researchers from Columbia University reported in the April 5, 2018, issue of Cell Stem Cell.
The Cancer Genome Atlas (TCGA), a comprehensive program that used sequencing to understand the genomic landscapes of 33 different tumor types, published its results Thursday in almost 30 papers in a half dozen different Cell Press journals.
Short interfering RNAs that were directed against a conserved region of flaviviruses, when delivered to the brain, enabled mice to fight off West Nile virus (WNV) in both the brain and the body, and develop a durable immune response. Researchers from Yale University reported those findings in the March 29, 2018, issue of Cell Host & Microbe.
Immune responses to gut bacteria may initiate systemic lupus erythematosus (lupus) in susceptible individuals. Individuals who go on to develop lupus have autoantibodies years before the onset of symptoms, and the earliest detectable antibodies are often those to the RNA-binding protein Ro60. Scientists from Yale University and the NIH investigated potential sources of Ro60 antigen, and they showed that several species of commensal bacteria express bacterial versions of Ro60.
Physiologically, antibodies are one of the major weapons the body deploys against infection. And the very first Nobel Prize in Physiology or Medicine, in 1901, was awarded to Emil Adolf von Behring for antibodies (in the form of serum therapy) against the diphtheria-causing Corynebacterium diphtheriae. So it is perhaps surprising that in the 117 years since, as far as antibiotic therapeutics go, small molecules have largely been the name of the game.
